Results for tag: "Xultophy"

Xultophy is a market of endocrine and metabolic disorder drugs. It is a combination of insulin degludec and liraglutide, two drugs used to treat type 2 diabetes. Xultophy is designed to help people with type 2 diabetes achieve better glycemic control with fewer injections and fewer side effects. It is a once-daily injection that helps to reduce the risk of hypoglycemia and weight gain. Xultophy is also used to reduce the risk of cardiovascular events in people with type 2 diabetes. Xultophy is a relatively new market, but it is growing rapidly. It is becoming increasingly popular among people with type 2 diabetes, as it offers a convenient and effective way to manage their condition. Companies in the Xultophy market include Novo Nordisk, Eli Lilly, Sanofi, and Merck. Show Less Read more